Hikma Pharmaceuticals (FRA:H5P) Debt-to-Equity : 0.54 (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Hikma Pharmaceuticals Debt-to-Equity?

Hikma Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €148 Mil. Hikma Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €945 Mil. Hikma Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €2,016 Mil. Hikma Pharmaceuticals's debt to equity for the quarter that ended in Dec. 2023 was 0.54.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Hikma Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

FRA:H5P' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.32 Med: 0.45 Max: 0.6
Current: 0.54

During the past 13 years, the highest Debt-to-Equity Ratio of Hikma Pharmaceuticals was 0.60. The lowest was 0.32. And the median was 0.45.

FRA:H5P's Debt-to-Equity is ranked worse than
71.31% of 826 companies
in the Drug Manufacturers industry
Industry Median: 0.27 vs FRA:H5P: 0.54

Hikma Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Hikma Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hikma Pharmaceuticals Debt-to-Equity Chart

Hikma Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.32

0.44

0.35

0.60

0.54

Hikma Pharmaceuticals Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.35	0.71	0.60	0.60	0.54

Competitive Comparison of Hikma Pharmaceuticals's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Hikma Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hikma Pharmaceuticals's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hikma Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Hikma Pharmaceuticals's Debt-to-Equity falls into.

Hikma Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Hikma Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(147.637	+	944.51)	/	2015.566
	=	0.54

Hikma Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(147.637	+	944.51)	/	2015.566
	=	0.54

Hikma Pharmaceuticals (FRA:H5P) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Hikma Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Hikma Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Hikma Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hikma Pharmaceuticals PLC (FRA:H5P) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

HKMPY:USA HKMPF:USA HIKl:UK HIK:UK

Address

1 New Burlington Place, London, GBR, W1S 2HR

Website

https://www.hikma.com

Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded and non-branded, in-licensed pharmaceutical products. The firm operates in three segments: injectables, generics, and branded. The majority of the revenue for the company is generated from its injectables segment under which it supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue generating market followed by Middle East and North Africa, United Kingdom, Europe and the rest of the world.

Hikma Pharmaceuticals Headlines

No Headlines